Search
Search Results
##search.searchResults.foundPlural##
-
OUTLINE OF IRON METABOLISM, WITH EMPHASIS TO ERYTHROID CELLS iron Metabolism
2292PDF: 1127Html: 850 -
THE HISTORY OF DEFERIPRONE (L1) AND THE COMPLETE TREATMENT OF IRON OVERLOAD IN THALASSAEMIA The history and roles of deferiprone
2493PDF: 1627HTML: 696 -
-
MYELODYSPLASTIC SYNDROMES AND IRON CHELATION THERAPY
3614PDF: 1334HTML: 2083Fig.1: 231Fig. 2: 226 -
ACQUIRED REFRACTORY IRON DEFICIENCY
3590PDF: 1250HTML: 1272 -
JUSTIFICATION OF UNIVERSAL IRON SUPPLEMENTATION FOR INFANTS 6-12 MONTHS IN REGIONS WITH A HIGH PREVALENCE OF THALASSEMIA Iron Supplementation for Infants 6-12 months in Regions with a High Prevalence of Thalassemia
3132PDF: 639Suppl. Files: 300HTML: 275 -
DEFERASIROX: OVER A DECADE OF EXPERIENCE IN THALASSEMIA
3091PDF: 1628HTML: 362 -
IRON DEFICIENCY ANAEMIA AMONG PRE-SCHOOL CHILDREN WITH SICKLE CELL ANAEMIA: STILL A RARE DIAGNOSIS?
1480PDF: 852HTML: 2941cover leer: 161 -
-
LIVER IRON CONTENT IN INDIVIDUALS WITH LIVER IRON CONTENT IN INDIVIDUALS WITH Β-THALASSEMIA TRAIT AND HYPERFERRITINEMIA: ROLE OF METABOLIC ALTERATIONS, HFE GENOTYPES, AND CIRRHOSIS.: ROLE OF METABOLIC ALTERATIONS, HFE GENOTYPES, AND CIRRHOSIS. Β-THALASSEMIA TRAIT AND HYPERFERRITINEMIA
235PDF: 274Suppl. Files: 24HTML: 6 -
THERAPEUTIC VALUE OF COMBINED THERAPY WITH DEFERASIROX AND SILYMARIN ON IRON OVERLOAD IN CHILDREN WITH BETA THALASSEMIA
2795PDF: 861HTML: 15023Therapeutic Value of Combined Therapy with Deferasirox and Silymarin on Iron Overload in Children with Beta Thalassemia: 337 -
PREVALENCE OF ANEMIA, IRON DEFICIENCY, AND IRON DEFICIENCY ANEMIA AND DIAGNOSTIC PERFORMANCE OF HEMATOLOGIC AND BIOCHEMICAL MARKERS OF SIDEROPENIA IN 1- TO 5-YEAR-OLD CHILDREN IN THRACE GREECE Prevalence of ID, IDA and anemia in Greek Thrace
2134PDF: 923HTML: 480 -
THE ROLE OF THE CAROTID DOPPLER EXAMINATION IN THE EVALUATION OF ATHEROSCLEROTIC CHANGES IN BETA THALASSEMIA PATIENTS
2234PDF: 1014HTML: 3067Untitled: 234 -
GLUCOSE HOMEOSTASIS AND ΑSSESSMENT OF Β-CELL FUNCTION BY 3-HOUR ORAL GLUCOSE TOLERANCE (OGTT) IN PATIENTS WITH Β-THALASSEMIA MAJOR WITH SERUM FERRITIN BELOW 1,000 NG/DL: RESULTS FROM A SINGLE ICET-A CENTRE OGTT in thalassemia and iron overload
4019PDF: 1161HTML: 466 -
EXERCISE STRESS ECHOCARDIOGRAPHY WITH TISSUE DOPPLER IMAGING (TDI) DETECTS EARLY SYSTOLIC DYSFUNCTION IN BETA-THALASSEMIA MAJOR PATIENTS WITHOUT CARDIAC IRON OVERLOAD
1392PDF: 832HTML: 7885Manuscript after revision: 257Barbero10328-36310-after revision: 252 -
PREVALENCE OF ALPHA THALASSEMIA IN MICROCYTIC ANEMIA: A TERTIARY CARE EXPERIENCE FROM NORTH INDIA
2508PDF: 1262HTML: 4851table: 224fig 1: 240fig 2: 191 -
A A RETROSPECTIVE LONG-TERM STUDY ON AGE AT MENARCHE AND MENSTRUAL CHARACTERISTICS IN 85 YOUNG WOMEN WITH TRANSFUSION-DEPENDENT Β-THALASSEMIA (TDT) BORN BETWEEN 1965 AND 1995 Long-Term Study on Age at Menarche and Menstrual Characteristics in patients with TDT
1608PDF: 536HTML: 264 -
COMPARATIVE STUDY ON THE MEASUREMENT OF LIVER T2* VALUES OF THALASSEMIA PATIENTS AND THE CLINICAL GRADING OF LIVER IRON CONCENTRATION BY DIFFERENT POST-PROCESSING SOFTWARE MEASUREMENT OF LIVER T2* VALUES OF THALASSEMIA
2199PDF: 644HTML: 299 -
CONCISE REVIEW ON THE FREQUENCY, MAJOR RISK FACTORS AND SURVEILLANCE OF HEPATOCELLULAR CARCINOMA (HCC) IN ?-THALASSEMIAS: PAST, PRESENT AND FUTURE PERSPECTIVES Thalassaemia transfusion dependent, Hepatitis C, hepatocarcinoma.
4359PDF: 1553HTML: 465 -
THALIDOMIDE AMELIORATES ERYTHROPOIESIS AND IRON HOMEOSTASIS IN TRANSFUSION-DEPENDENT β-THALASSEMIA Thalidomide ameliorates erythropoiesis and iron homeostasis
1460PDF: 1459PDF: 1037HTML: 228 -
ZYGOMYCOSIS IN IMMUNOCOMPROMISED NON-HAEMATOLOGICAL PATIENTS
2951PDF: 991HTML: 7493 -
GROWTH AND ENDOCRINE FUNCTION IN TUNISIAN THALASSEMIA MAJOR PATIENTS
4706PDF: 1055HTML: 476TABLE: 204FIGURES: 275 -







